Denali Therapeutics Inc. Operating Lease, Payments
Denali Therapeutics Inc. (DNLI) reported Operating Lease, Payments of $3.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-06
- Denali Therapeutics Inc. operating lease, payments for the quarter ending 2026-06-30 was $3.00M, a 3.45% increase year-over-year.
- Denali Therapeutics Inc. operating lease, payments for the quarter ending 2026-03-31 was $3.00M, a 3.45% increase year-over-year.
- Denali Therapeutics Inc. operating lease, payments for the quarter ending 2025-12-31 was $2.98M, a 3.29% increase year-over-year.
- Denali Therapeutics Inc. operating lease, payments for the quarter ending 2025-09-30 was $2.98M, a 3.29% increase year-over-year.
- Denali Therapeutics Inc. operating lease, payments for fiscal 2025 was $11.79M, a 3.29% increase from fiscal 2024.
- Denali Therapeutics Inc. operating lease, payments for fiscal 2024 was $11.42M, a 0.63% increase from fiscal 2023.
- Denali Therapeutics Inc. operating lease, payments for fiscal 2023 was $11.35M, a 1.39% increase from fiscal 2022.
- Denali Therapeutics Inc. operating lease, payments for fiscal 2022 was $11.19M, a 8.25% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 3 month as first filed | Operating Lease, Payments 6 month | Operating Lease, Payments 6 month as first filed | Operating Lease, Payments 9 month | Operating Lease, Payments 9 month as first filed | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.00M 10-Q · filed 2026-08-06 | $6.00M 10-Q · filed 2026-08-06 | $8.98M derived: sum of 3 quarters · filed 2026-08-06 | $11.96M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $3.00M 10-Q · filed 2026-05-07 | $5.98M derived: sum of 2 quarters · filed 2026-05-07 | $8.96M derived: sum of 3 quarters · filed 2026-05-07 | $11.86M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.96M derived: sum of 2 quarters · filed 2026-02-26 | $8.86M derived: sum of 3 quarters · filed 2026-08-06 | $11.79M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $2.98M 10-Q · filed 2025-11-06 | $5.88M derived: sum of 2 quarters · filed 2026-08-06 | $8.81M 10-Q · filed 2025-11-06 | $11.66M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $2.90M 10-Q · filed 2026-08-06 | $2.95M 10-Q · filed 2025-08-11 | $5.80M 10-Q · filed 2026-08-06 | $5.83M 10-Q · filed 2025-08-11 | $8.69M derived: sum of 3 quarters · filed 2026-08-06 | $11.57M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $2.90M 10-Q · filed 2026-05-07 | $2.88M 10-Q · filed 2025-05-06 | $5.79M derived: sum of 2 quarters · filed 2026-05-07 | $8.67M derived: sum of 3 quarters · filed 2026-05-07 | $11.52M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.77M derived: sum of 2 quarters · filed 2026-02-26 | $8.62M derived: sum of 3 quarters · filed 2026-02-26 | $11.42M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $2.88M 10-Q · filed 2025-11-06 | $5.74M derived: sum of 2 quarters · filed 2025-11-06 | $8.53M 10-Q · filed 2025-11-06 | $11.32M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $2.85M 10-Q · filed 2025-08-11 | $5.65M 10-Q · filed 2025-08-11 | $8.44M derived: sum of 3 quarters · filed 2026-02-26 | $11.23M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $2.79M 10-Q · filed 2025-05-06 | $5.59M derived: sum of 2 quarters · filed 2026-02-26 | $8.38M derived: sum of 3 quarters · filed 2026-02-26 | $11.14M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.59M derived: sum of 2 quarters · filed 2026-02-26 | $8.35M derived: sum of 3 quarters · filed 2026-02-26 | $11.35M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $2.79M 10-Q · filed 2024-11-06 | $5.56M derived: sum of 2 quarters · filed 2024-11-06 | $8.55M 10-Q · filed 2024-11-06 | $11.55M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $2.76M 10-Q · filed 2024-08-01 | $5.76M 10-Q · filed 2024-08-01 | $8.76M derived: sum of 3 quarters · filed 2025-02-27 | $11.65M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $3.00M 10-Q · filed 2024-05-07 | $5.99M derived: sum of 2 quarters · filed 2025-02-27 | $8.89M derived: sum of 3 quarters · filed 2025-02-27 | $11.57M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $5.89M derived: sum of 2 quarters · filed 2025-02-27 | $8.57M derived: sum of 3 quarters · filed 2025-02-27 | $11.19M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $2.90M 10-Q · filed 2023-11-07 | $5.58M derived: sum of 2 quarters · filed 2023-11-07 | $8.19M 10-Q · filed 2023-11-07 | $10.81M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-06-30 | $2.68M 10-Q · filed 2023-08-08 | $5.29M 10-Q · filed 2023-08-08 | $7.91M derived: sum of 3 quarters · filed 2024-02-28 | $10.53M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-03-31 | $2.62M 10-Q · filed 2023-05-08 | $5.24M derived: sum of 2 quarters · filed 2024-02-28 | $7.86M derived: sum of 3 quarters · filed 2024-02-28 | $10.42M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2021-12-31 | $2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $5.24M derived: sum of 2 quarters · filed 2024-02-28 | $7.80M derived: sum of 3 quarters · filed 2024-02-28 | $10.34M 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | $2.62M 10-Q · filed 2022-11-03 | $5.18M derived: sum of 2 quarters · filed 2022-11-03 | $7.72M 10-Q · filed 2022-11-03 | $10.25M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-06-30 | $2.56M 10-Q · filed 2022-08-08 | $5.10M 10-Q · filed 2022-08-08 | $5.10M 10-Q · filed 2021-08-04 | $7.63M derived: sum of 3 quarters · filed 2023-02-27 | $10.17M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-03-31 | $2.54M 10-Q · filed 2022-05-05 | $2.50M 10-Q · filed 2021-05-05 | $5.07M derived: sum of 2 quarters · filed 2023-02-27 | $7.61M derived: sum of 3 quarters · filed 2023-02-27 | $10.11M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2020-12-31 | $2.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $5.07M derived: sum of 2 quarters · filed 2023-02-27 | $7.57M derived: sum of 3 quarters · filed 2023-02-27 | $9.74M 10-K · filed 2023-02-27 | $9.70M 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $2.54M 10-Q · filed 2021-11-04 | $5.04M derived: sum of 2 quarters · filed 2021-11-04 | $7.20M 10-Q · filed 2021-11-04 | $7.20M 10-Q · filed 2020-11-05 | $9.26M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $4.70M 10-Q · filed 2021-08-04 | $6.72M derived: sum of 3 quarters · filed 2022-02-28 | $8.22M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $2.20M 10-Q · filed 2021-05-05 | $4.22M derived: sum of 2 quarters · filed 2022-02-28 | $5.72M derived: sum of 3 quarters · filed 2022-02-28 | $7.62M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.52M derived: sum of 2 quarters · filed 2022-02-28 | $5.42M derived: sum of 3 quarters · filed 2022-02-28 | $5.42M 10-K · filed 2022-02-28 | $5.40M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $3.40M derived: sum of 2 quarters · filed 2020-11-05 | $3.40M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $1.90M 10-Q · filed 2019-08-06 | $1.90M 10-Q · filed 2020-08-07 | ||||||
| 2019-03-31 | $700.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |